ERBB2 and breast cancer: HER2-specific monoclonal antibodies (mAbs) demonstrated favorable clinical outcomes in HER2-positive breast cancer (IHC score 3+ or IHC2+ with gene amplification positive on an in situ hybridization (ISH)).